Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YZJT-1705
- Development stage
- Phase 2
- Lead developer
- Shanghai Institute of Materia Medica
- Modality
- Small Molecules
- Administration
- Injection, Subcutaneous (supported By Trial Design)[1]
01
Overview
YZJT-1705 is an investigational drug developed for postoperative analgesia, specifically targeting pain management in patients undergoing abdominal surgery. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics (PK), and efficacy as an analgesic. The drug is administered as an injection and has been compared to ropivacaine hydrochloride injection in clinical studies. The primary developer is the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, with Jiangsu Yangtze River Pharmaceutical Group also involved in sponsorship and development activities[1]. Its precise mechanism of action or molecular target has not been publicly disclosed.
Beyond the preview
Go deeper on YZJT-1705.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YZJT-1705.